TSE:4967

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Kobayashi Pharmaceutical

Market Cap

JP¥755.1b

Last Updated

2021/06/18 08:14 UTC

Data Sources

Company Financials +

Executive Summary

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. More Details

Rewards

Earnings are forecast to grow 3.52% per year

Risk Analysis

No risks detected for 4967 from our risk checks.


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has Kobayashi Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4967 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4967's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

3.2%

4967

1.3%

JP Personal Products

0.4%

JP Market


1 Year Return

-3.8%

4967

2.0%

JP Personal Products

22.6%

JP Market

Return vs Industry: 4967 underperformed the JP Personal Products industry which returned 2% over the past year.

Return vs Market: 4967 underperformed the JP Market which returned 22.6% over the past year.


Shareholder returns

4967IndustryMarket
7 Day3.2%1.3%0.4%
30 Day0.5%5.4%3.6%
90 Day-6.6%-0.7%-2.3%
1 Year-3.1%-3.8%3.3%2.0%25.3%22.6%
3 Year3.4%0.9%-15.1%-18.2%20.3%12.1%
5 Year136.9%127.1%88.8%76.3%78.4%58.9%

Long-Term Price Volatility Vs. Market

How volatile is Kobayashi Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kobayashi Pharmaceutical undervalued compared to its fair value and its price relative to the market?

39.76x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 4967 (¥9660) is trading above our estimate of fair value (¥3031.67)

Significantly Below Fair Value: 4967 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4967 is poor value based on its PE Ratio (39.6x) compared to the JP Personal Products industry average (35.8x).

PE vs Market: 4967 is poor value based on its PE Ratio (39.6x) compared to the JP market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: 4967 is poor value based on its PEG Ratio (11.2x)


Price to Book Ratio

PB vs Industry: 4967 is overvalued based on its PB Ratio (4.1x) compared to the JP Personal Products industry average (3x).


Future Growth

How is Kobayashi Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

3.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4967's forecast earnings growth (3.5% per year) is above the savings rate (0%).

Earnings vs Market: 4967's earnings (3.5% per year) are forecast to grow slower than the JP market (12.9% per year).

High Growth Earnings: 4967's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4967's revenue (2.9% per year) is forecast to grow slower than the JP market (5.2% per year).

High Growth Revenue: 4967's revenue (2.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4967's Return on Equity is forecast to be low in 3 years time (9.9%).


Past Performance

How has Kobayashi Pharmaceutical performed over the past 5 years?

6.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4967 has high quality earnings.

Growing Profit Margin: 4967's current net profit margins (12.8%) are higher than last year (11.5%).


Past Earnings Growth Analysis

Earnings Trend: 4967's earnings have grown by 6% per year over the past 5 years.

Accelerating Growth: 4967's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4967 had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Personal Products industry average (-17.7%).


Return on Equity

High ROE: 4967's Return on Equity (10.3%) is considered low.


Financial Health

How is Kobayashi Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 4967's short term assets (¥161.1B) exceed its short term liabilities (¥42.0B).

Long Term Liabilities: 4967's short term assets (¥161.1B) exceed its long term liabilities (¥6.0B).


Debt to Equity History and Analysis

Debt Level: 4967 is debt free.

Reducing Debt: 4967 has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.

Debt Coverage: 4967 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4967 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Kobayashi Pharmaceutical current dividend yield, its reliability and sustainability?

0.81%

Current Dividend Yield


Upcoming Dividend Payment

TodayJun 18 2021Ex Dividend DateJun 29 2021Dividend Pay DateSep 10 202173 days from Ex DividendBuy in the next 11 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4967's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.31%).

High Dividend: 4967's dividend (0.82%) is low compared to the top 25% of dividend payers in the JP market (2.99%).


Stability and Growth of Payments

Stable Dividend: 4967's dividends per share have been stable in the past 10 years.

Growing Dividend: 4967's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (31.5%), 4967's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.0yrs

Average board tenure


CEO

Kazumasa Kobayashi (81 yo)

17yrs

Tenure

JP¥293,000,000

Compensation

Mr. Kazumasa Kobayashi has been the Chairman of the Board and Chief Executive Officer of Kobayashi Pharmaceutical Co. LTD. since June 2004. Mr. Kobayashi served as the President of KOBAYASHI Pharmaceutical...


CEO Compensation Analysis

Compensation vs Market: Kazumasa's total compensation ($USD2.67M) is above average for companies of similar size in the JP market ($USD1.41M).

Compensation vs Earnings: Kazumasa's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 4967's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kobayashi Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kobayashi Pharmaceutical Co., Ltd.
  • Ticker: 4967
  • Exchange: TSE
  • Founded: 1886
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: JP¥755.055b
  • Shares outstanding: 78.16m
  • Website: https://www.kobayashi.co.jp

Number of Employees


Location

  • Kobayashi Pharmaceutical Co., Ltd.
  • KDX Kobayashi Doshomachi Building
  • 4-4-10, Doshomachi
  • Osaka
  • 541-0045
  • Japan

Listings


Biography

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 08:14
End of Day Share Price2021/06/18 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.